1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NINDS Small Business Program Areas of Interest - Therapeutics and Diagnostics Development for Neurological Disorders is sponsored by National Institute of Neurological Disorders and Stroke (NINDS) / NIH. The NINDS SBIR/STTR program funds small business concerns to conduct innovative neuroscience research and development with commercialization potential and public benefit.
This includes therapeutics and diagnostics development for neurological disorders, which can encompass preclinical drug development for Alzheimer's disease.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
[](https://www. ninds. nih.
gov/funding/ninds-small-business-program/ninds-small-business-program-areas-interest) See NOT-NS-18-002 for further details on factors impacting NIND SBIR/STTR funding decisions. ## NINDS Small Business Program Areas of Interest Examples of research topics within the mission of NINDS that may be of interest to small businesses are shown below. This list is not all inclusive and some research projects fall into multiple categories.
For more information on choosing a research area, please see the Submitting a Small Business Application. ### General Areas of Interest * Therapeutics and Diagnostics Development for Neurological Disorders, including biomarker and diagnostic assays, therapeutics (drugs, biologics, and/or devices) for treatment of neurological disorders, and technologies/methodologies to deliver therapeutics to the central nervous system.
* Clinical and Rehabilitation Tools, including intraoperative technologies for neurosurgeons, rehabilitation devices and programs for neurological disorders, and brain monitoring systems. * Technology and Tools, including imaging technologies to image the nervous system, neural interface technologies, and tools for neuroscience research and drug development.
### Specific Areas of Interest * Novel and innovative technologies that are new to the SBIR or STTR programs. * Technologies coming to the SBIR or STTR programs for their first indication or market opportunity. * Companies and applicants that are new to the SBIR and STTR programs.
## Cooperative Translational Agreements and NIH-Wide Initiatives ### Cooperative Translational Agreements | Blueprint Neurotherapeutics Network (BPN) | Provides both funding and in-kind support for small molecule drug discovery and development, from hit-to-lead chemistry through phase I clinical testing.
The program offers funding, access to NIH-funded contract research organizations (CROs), and consultants with expertise in various aspects of drug discovery and development.
| Contact: Pascal Laeng | | Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) | Dedicated to biotechnology product- and biologics-based therapies, which broadly include modalities such as peptides, proteins, oligonucleotides, gene therapies, and cell therapies.
The program supports lead optimization, IND-enabling studies, and phase I clinical testing by providing grant funding as well as in-kind access to NIH-funded contract research organizations (CROs) and consultants with drug development expertise.
| Contact: Chris Boshoff | | Helping to End Addiction Long-term®Initiative (NIH HEAL Initiative) | The Helping to End Addiction Long-term® Initiative | NIH HEAL Initiative, is an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. Almost every NIH Institute and Center is accelerating research to address this public health emergency from all angles.
The initiative is funding hundreds of projects nationwide. Researchers are taking a variety of approaches to tackle the opioid epidemic through: “Understanding, managing, and treating pain” and “Improving prevention and treatment for opioid misuse and addiction”.
| Contact:Emily Caporello | | Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) | Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) refers to the most common forms of dementia.
NINDS collaborates with NIH’s National Institute on Aging (NIA), the lead NIH Institute for Alzheimer’s disease (AD) research, to establish research priorities and fund biomedical research in AD as well as several Alzheimer’s disease-related dementias (ADRDs).
| Contact:Annette Gilchrist | | Blueprint MedTech | Innovators developing groundbreaking medical device technologies face a number of challenges along the translational path from bench to bedside. The Blueprint MedTech program is an NIH incubator that aims to address such challenges and support the innovators by accelerating the development of cutting-edge medical devices to diagnose and/or treat disorders of the nervous system.
The mission of the program is to catalyze the translation of novel technologies from early-stage development to readiness for first-in-human clinical studies. The overarching goal of the Blueprint MedTech program is to accelerate patient access to groundbreaking, safe, and effective medical devices.
The program will provide support to sufficiently develop and de-risk technologies to the point where additional investments are warranted from industry partners, investors, and government. | Contact: Blueprint MedTech | ### NINDS Small Business Program Contact Information
According to the current listing, eligibility includes: Small business concerns conducting innovative neuroscience research and development. Confirm the full requirements in the official notice before applying.
The current listing shows varies by project; SBIR/STTR Phase I awards typically up to $300,000, Phase II up to $2 million (higher for AD/ADRD research through NIA). Verify award ceilings, matching requirements, and allowable costs in the official notice.
NINDS Small Business Program Areas of Interest - Therapeutics and Diagnostics Development for Neurological Disorders is funded by National Institute of Neurological Disorders and Stroke (NINDS) / NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed) is sponsored by National Institute of Neurological Disorders and Stroke (NINDS) / NIH. This is a non-competitive funding opportunity intended to fund a single award to support the renewal of the Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States.
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) is sponsored by National Institute of Neurological Disorders and Stroke (NINDS) / NIH. Part of the HEAL (Helping to End Addiction Long-term) Initiative, this opportunity focuses on the development of non-addictive analgesic therapeutics, including small molecules and biologics, to treat pain.
PAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read article